Nicola Hanania on Muck Rack

Nicola Hanania

Texas
As seen in: Respiratory Medicine, Color Research & Application, Wiley Online Library, MDPI, Taylor & Francis Online, The New England Journal of Medicine, The Lancet, Dove Medical Press, Healio Pulmonology, HCP Live, Dialnet - Universidad de La Rioja and
Professor, Director, Airways Clinical Research Center, Baylor College of Medicine, Chief, PCCM, BT Hosp. Editor-in-Chief, Respiratory Medicine #resmedjournal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nicola

Contact Nicola, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Inflammation Without Borders: The Interconnected Pathways of Asthma and Heart Disease

|
By Muhammad Adrish, Nicola Hanania
| Dialnet - Universidad de La Rioja
Ayuda Buscar en la ayuda Buscar en la ayuda
Open in Who Shared View Duplicates (679) Issue with article?

Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils

|
By Nicola Hanania, Felix J.F. Herth
| ersnet.org
Review Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils Article Figures & Tables Info & Metrics Introduction Asthma is a chronic, inflammatory disease of the airways, currently estimated to affect 300 million people globally [1]. Asthma is typically characterised by airway hyperresponsiveness, chronic airway inflammation and reversible airway obstruction, which can become persistent [1].
Open in Who Shared Issue with article?

Prospecting the IL-33 Pathway for COPD Care, with Nicola Hanania, MD, MS

|
By Nicola Hanania, Kevin Kunzmann
| consultantlive.com
Mepolizumab (Nucala) and dupilumab (Dupixent) made history as the first biologic therapies indicated to treat eligible patients with COPD in the last 2 years.1,2 The recency of those pharmaceutical breakthroughs highlights not only the previous dearth of treatment advancement for patients with obstructive lung disease — it also showed how much more clinicians must uncover about the pathophysiology of COPD.
Open in Who Shared View Duplicates (2) Issue with article?
See all 99 licensed articles (137 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified